Diabetes research and clinical practice最新文献

{"title":"Intravitreal anti-VEGF therapy and risk of limb complications in individuals with diabetic eye disease","authors":"Alexander T. Hong ,&nbsp;Ivan Y. Luu ,&nbsp;Forest Lin ,&nbsp;Tze-Woei Tan ,&nbsp;Brian C. Toy","doi":"10.1016/j.diabres.2025.112457","DOIUrl":"10.1016/j.diabres.2025.112457","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate the association between intravitreal anti-VEGF therapy and lower extremity complications in diabetic eye disease (DED), and compare risks among ranibizumab, aflibercept, and bevacizumab.</div></div><div><h3>Methods</h3><div>This retrospective cohort study used a U.S. electronic health records network. Adults with DED receiving ≥3 intravitreal anti-VEGF injections (IVI) were compared to those receiving ≤2 (controls). Outcomes included diabetic foot ulcer (DFU) and lower extremity amputation (LEA). Propensity score matching (1:1) balanced baseline characteristics. Cox models estimated hazard ratios (HRs) with 95 % confidence intervals (CIs) for LEA, above-ankle LEA, and DFU in the overall cohort and subgroups with proliferative diabetic retinopathy (PDR), peripheral artery disease (PAD), end-stage renal disease (ESRD), or prior DFUs.</div></div><div><h3>Results</h3><div>Of 448,100 individuals with DED, 35,269 received ≥3 injections; 34,070 remained in each group after matching. IVI was associated with higher risk of LEA (HR 1.54 [95 % CI 1.38–1.72]), above-ankle LEA (HR 1.31 [1.08–1.59]), and DFU (HR 1.36 [1.30–1.42]) versus controls. LEA risk was greater in IVI versus control subgroups with PDR, PAD, ESRD, or DFUs. Risks were similar across agents.</div></div><div><h3>Conclusions</h3><div>Anti-VEGF therapy in DED was linked to increased DFU and LEA risk, especially in high-risk subgroups. Prospective studies are needed for confirmation.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112457"},"PeriodicalIF":7.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of transitioning from conventional blood glucose monitoring to continuous glucose monitoring on glycemic control and self-management in adults with type 2 diabetes on oral glucose-lowering medications","authors":"Ayman Al Hayek ,&nbsp;David C. Klonoff ,&nbsp;Wael M. Al Zahrani ,&nbsp;Abdulghani H. Al Saeed ,&nbsp;Mohammed A. Al Dawish","doi":"10.1016/j.diabres.2025.112458","DOIUrl":"10.1016/j.diabres.2025.112458","url":null,"abstract":"<div><h3>Background</h3><div>Despite advances, glycemic control in people with type 2 diabetes (PwT2D) treated with oral antidiabetic medications (ADMs) often remains suboptimal. Continuous glucose monitoring (CGM) has shown promise in diabetes management, offering real-time insights into glucose trends. This study evaluates the impact of transitioning from conventional self-monitoring of blood glucose (SMBG) to CGM on glycemic outcomes and self-management in PwT2D receiving oral ADMs.</div></div><div><h3>Methods</h3><div>In this prospective study, 108 PwT2D managed with oral ADMs were enrolled. Participants transitioned from conventional SMBG to the FreeStyle Libre 2 CGM system for 12 weeks. Clinical, metabolic, and glycemic parameters, alongside patient-reported outcomes assessed by the Impact of Glucose Monitoring on Self-Management Scale (IGMSS), were recorded at baseline and study endpoint.</div></div><div><h3>Results</h3><div>CGM use was associated with significant improvement across multiple glycemic and self-management metrics. Over 12 weeks, HbA1c decreased from 7.93 % to 7.31 % (<em>p &lt; 0.001</em>), and mean capillary glucose levels decreased from 191 mg/dL to 180 mg/dL (<em>p &lt; 0.001</em>). Time in range reached 70 % (SD = 6.86). Self-management, as measured by the IGMSS, improved—with Capability scores rising from 16.1 to 30.3, Opportunity from 19.8 to 35, and Motivation from 12.3 to 23.3 (<em>all p &lt; 0.001</em>). The scale score increased from 42 to 75.6 (<em>p &lt; 0.001</em>). Additionally, longer diabetes duration (<em>p = 0.024</em>) and more frequent SMBG (<em>p = 0.012</em>) were associated with lower endpoint IGMSS scores, whereas the presence of co-morbidities was linked to higher scores (<em>p = 0.03</em>).</div></div><div><h3>Conclusion</h3><div>Switching from conventional SMBG to CGM significantly improved glycemic control and self-management in PwT2D treated with oral ADMs. This observation highlights the potential for broader integration of CGM into this population.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112458"},"PeriodicalIF":7.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to comments on tirzepatide versus bariatric metabolic surgery in adults with obstructive sleep apnea and obesity","authors":"Jheng-Yan Wu ,&nbsp;Yu-Min Lin ,&nbsp;Wan-Hsuan Hsu ,&nbsp;Ting-Hui Liu ,&nbsp;Ya-Wen Tsai ,&nbsp;Po-Yu Huang ,&nbsp;Min-Hsiang Chuang ,&nbsp;Tsung Yu ,&nbsp;Chih-Cheng Lai","doi":"10.1016/j.diabres.2025.112459","DOIUrl":"10.1016/j.diabres.2025.112459","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112459"},"PeriodicalIF":7.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting stimulated C-peptide in type 1 diabetes using machine learning: a web-based tool from the T1D exchange registry","authors":"Emre Sedar Saygili ,&nbsp;Adnan Batman ,&nbsp;Ersen Karakilic","doi":"10.1016/j.diabres.2025.112453","DOIUrl":"10.1016/j.diabres.2025.112453","url":null,"abstract":"<div><h3>Aims</h3><div>The mixed-meal tolerance test (MMTT), though considered the gold standard for evaluating residual beta-cell function in type 1 diabetes mellitus (T1D), is impractical for routine use. We aimed to develop and validate a machine learning (ML) model to predict MMTT-stimulated C-peptide categories using routine clinical data.</div></div><div><h3>Methods</h3><div>Data from 319 individuals in the T1D Exchange Registry with complete MMTT and clinical information were analyzed. The cohort was randomly split into training (70%) and test (30%) sets. Five clinical variables—age at diagnosis, diabetes duration, HbA1c, non-fasting glucose, and non-fasting C-peptide—were selected via recursive feature elimination. Four ML algorithms (random forest [RF], XGBoost, LightGBM, and ordinal logistic regression) were trained with 10-fold cross-validation.</div></div><div><h3>Results</h3><div>The RF model showed the highest performance: AUC 0.94 (95% CI: 0.92–0.96), sensitivity 0.84 (95% CI: 0.80–0.89), and specificity 0.92 (95% CI: 0.90–0.94) in cross-validation. In the test set, AUC was 0.97, sensitivity 88%, and specificity 94%. Notably, 17.7% of individuals with undetectable non-fasting C-peptide had measurable levels after MMTT.</div></div><div><h3>Conclusions</h3><div>This ML model provides a practical, non-invasive tool for estimating beta-cell function in T1D and is available online at <span><span>https://cpeptide.streamlit.app</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112453"},"PeriodicalIF":7.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of socioeconomic status and hospital efficiency in Type-1 diabetic patients with ketoacidosis or diabetic coma: a secondary data analysis comparing nation-wide paediatric and adult admissions in France","authors":"Yuanchen Xu ,&nbsp;Karine Chevreul ,&nbsp;Christel Dindorf ,&nbsp;Élise Bismuth ,&nbsp;Jean-Claude Carel ,&nbsp;Morgane Michel","doi":"10.1016/j.diabres.2025.112450","DOIUrl":"10.1016/j.diabres.2025.112450","url":null,"abstract":"<div><h3>Aims</h3><div>To study the association between socioeconomic status (SES) and hospital efficiency in Type 1 diabetes mellitus patients admitted for ketoacidosis or diabetic coma in mainland France, overall and in adults <em>versus</em> children.</div></div><div><h3>Methods</h3><div>An observational study was carried out using exhaustive national hospital discharge databases. It included all admissions discharged from 2013 to 2019. SES was assessed using an ecological measure divided into national quintiles, and efficiency by variations in patients’ length of stay (LOS) compared to mean national LOS and a comparison of production costs and revenues. Multilevel multivariable analyses were carried out to study the association.</div></div><div><h3>Results</h3><div>67,100 admissions were included. Multivariable analyses found a significant association between efficiency outcomes, SES and age. Compared to other age groups, children under 5 had higher LOS than the national mean and incurred higher costs than what hospitals were paid regardless of SES. In adults, there was a significant interaction between SES and age group, leading to significantly increased LOS and costs in adults from intermediate and/or lower SES groups.</div></div><div><h3>Conclusions</h3><div>Current payment methods using diagnosis-related groups may not adequately reflect the burden of Type 1 diabetes mellitus patients admitted for ketoacidosis or diabetic coma on hospitals.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112450"},"PeriodicalIF":7.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study","authors":"Celestino Sardu ,&nbsp;Ludovica Vittoria Marfella ,&nbsp;Luca Rinaldi ,&nbsp;Ferdinando Carlo Sasso ,&nbsp;Domenico Cozzolino ,&nbsp;Francesco Nappo ,&nbsp;Ausilia Sellitto ,&nbsp;Ciro Romano ,&nbsp;Caterina Carusone ,&nbsp;Nunzia D’Onofrio ,&nbsp;Maria Consiglia Trotta ,&nbsp;Joshua Riccio ,&nbsp;Domenico Cioffi ,&nbsp;Mario Volpicelli ,&nbsp;Carmine La Marca ,&nbsp;Natale Marrazzo ,&nbsp;Valerio Giordano ,&nbsp;Carlo Fumagalli ,&nbsp;Alessandro Landolfi ,&nbsp;Marianna Abitabile ,&nbsp;Raffaele Marfella","doi":"10.1016/j.diabres.2025.112452","DOIUrl":"10.1016/j.diabres.2025.112452","url":null,"abstract":"<div><h3>Background</h3><div>Type-2-diabetes-mellitus (T2DM) impairs outcomes in patients undergoing cardiac-resynchronization-therapy-with-defibrillator (CRTd).<!--> <!-->While both sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have cardiovascular benefits, their combination impact in CRTd-treated T2DM patients remains unclear.</div></div><div><h3>Methods</h3><div>In this prospective multicenter observational study, 2,257 T2DM patients treated with CRTd were stratified into three groups: SGLT2i monotherapy (n 874), GLP-1RAs monotherapy (n 808), and combination therapy with GLP-1RAs/SGLT2i (n 575). Primary endpoints were CRT-response and heart failure (HF) hospitalizations at 1-year follow-up. Secondary endpoints included changes in glycemic control, renal function, inflammatory/oxidative markers, and cardiac deaths.</div></div><div><h3>Results</h3><div>At 1 year, the combination therapy group had significantly higher CRT-response rate (66.3 %) compared to SGLT2i (59.6 %) and GLP-1RAs (59.2 %) groups (p = 0.014), and lower HF-hospitalization rates (15.7 % vs. 23.5 % and 24.4 %, respectively; p = 0.001). Multivariate Cox analysis confirmed combination therapy as an independent predictor of CRT response (HR 1.659, CI 95 % [1.320–2.085]; p 0.001) and reduced HF hospitalizations (0.822, CI 95 % [0.751–0.966]; p0.012) at 1 year of follow-up.</div></div><div><h3>Conclusions</h3><div>In T2DM patients receiving CRTd, combination therapy with GLP-1RAs/SGLT2i was associated with improvements in cardiac function and clinical outcomes compared to monotherapy. GLP-1RAs/SGLT2i could optimize CRT responsiveness and reduce HF-hospitalizations in T2DM patients.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"228 ","pages":"Article 112452"},"PeriodicalIF":7.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Patients with type 2 diabetes who achieve reduced postprandial glucose levels during insulin intensive therapy may have a better recovery of β-cell function\". [Diabetes Res. Clin. Pract. 215 (2024) 111805].","authors":"Ping Chen, Qi Sun, Liying Xu, Hao Liu, Fengfei Li","doi":"10.1016/j.diabres.2025.112451","DOIUrl":"https://doi.org/10.1016/j.diabres.2025.112451","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"112451"},"PeriodicalIF":7.4,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic regulation of IL-33 in the obesity pathogenesis: Spatiotemporal specificity and functional paradoxes","authors":"Na Cui,&nbsp;Lijuan Jiang,&nbsp;Lingli Tang,&nbsp;Haoneng Tang","doi":"10.1016/j.diabres.2025.112455","DOIUrl":"10.1016/j.diabres.2025.112455","url":null,"abstract":"<div><div>Obesity is a complex chronic metabolic disease closely associated with inflammatory responses and insulin resistance. As a member of the IL-1 cytokine family, Interleukin-33(IL-33) binds to its receptor suppression of tumorigenicity 2 (ST2) and plays a crucial role in regulating the adipose tissue immune microenvironment and maintaining metabolic homeostasis. However, its role in obesity exhibits spatiotemporal specificity and functional paradoxes. Under physiological conditions, IL-33 activates regulatory T cells (Tregs) and type 2 innate lymphoid cells (ILC2s), promoting anti-inflammatory factors secretion and adipose thermogenesis to maintain metabolic homeostasis. In obesity, despite increased IL-33 expression in obese adipose tissue, its protective effects are impaired by effector cell dysfunction, sST2-mediated neutralization, and non-classical pathway activation, collectively termed the “expression-function paradox”. Notably, IL-33 exhibits tissue-specific effects in distinct organs, including adipose tissue, cardiac tissue, liver and lungs under obese conditions. This review systematically analyzes the spatiotemporal regulatory mechanisms, functional paradoxes, and therapeutic potential of IL-33 in obesity, offering new insights for targeting obesity and related metabolic disorders.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112455"},"PeriodicalIF":7.4,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbial signatures in type 2 diabetes are highly associated with geographic region, diet habits and common comorbidities: Insights from a bioinformatics analysis of Chinese population","authors":"Xiaoyi Li ,&nbsp;Kexin Ding ,&nbsp;Yujia Ma ,&nbsp;Han Xiao ,&nbsp;Yan Liu ,&nbsp;Guangfeng Wu ,&nbsp;Dafang Chen","doi":"10.1016/j.diabres.2025.112438","DOIUrl":"10.1016/j.diabres.2025.112438","url":null,"abstract":"<div><h3>Aims</h3><div>Emerging evidence implicates the gut microbiota in type 2 diabetes (T2D) development and their association with multiple host factors. This study aimed to explore the differences in gut microbiota between T2D patients and non-diabetic controls, and to estimate the relationship between host factors and specific microbial signatures in T2D.</div></div><div><h3>Methods</h3><div>16S rRNA gene sequencing was performed on fecal samples from 508 T2D patients and 1,538 controls in a Chinese population.</div></div><div><h3>Results</h3><div>We observed significant differences in microbial composition and diversity between T2D and controls, with 20 microbial signatures associated with T2D. Microbial co-occurrence networks revealed that T2D patients exhibited a distinct microbiome signatures pattern. Random forest models incorporating these microbial signatures and covariates improved accuracy of T2D classification. Furthermore, geographic region, diet habits of different staple food sources and coffee drinking habit, and common comorbidities, such as hypertension, were associated with specific microbial signatures.</div></div><div><h3>Conclusions</h3><div>Our study highlights the potential role of gut microbiota in T2D pathogenesis and provides clues that specific microbial signatures may serve as biomarkers for T2D diagnosis and personalized management in Chinese populations. The findings indicate that modifiable factors including dietary factors, living regions and common comorbidities may influence the gut microbiota, thereby affecting T2D development.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112438"},"PeriodicalIF":7.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of commercially available automated insulin delivery systems in pregnant people with type 1 diabetes","authors":"Angela Q. Pham ,&nbsp;Ildiko Lingvay ,&nbsp;Nicole Ahmadi ,&nbsp;Patricia C. Santiago-Munoz ,&nbsp;Marconi Abreu","doi":"10.1016/j.diabres.2025.112454","DOIUrl":"10.1016/j.diabres.2025.112454","url":null,"abstract":"<div><h3>Aims</h3><div>Automated insulin delivery (AID) systems are first-line therapy for type 1 diabetes, but commercially available AIDs in the United States are not approved for pregnancy. We aimed to compare glycemic control achieved during pregnancy by people with type 1 diabetes using AIDs versus standard of care therapy (multiple daily injections and sensor augmented pump therapy).</div></div><div><h3>Methods</h3><div>This was a retrospective cohort study of people with type 1 diabetes who used a continuous glucose monitor (CGM) during pregnancy. The primary outcome was time in range (TIR); time below range (TBR), time above range, and glucose standard deviation were secondary outcomes. Outcomes were compared using analysis of covariance.</div></div><div><h3>Results</h3><div>38 people were included: 21 treated with AIDs and 17 with standard of care. The mean antenatal TIR in the AID group was 68.5 ± 12.9 % compared to 55.7 ± 16.7 % (adjusted mean difference 7.9 %, 95 % CI: 0.8 to 15.0, p = 0.03). The AID group achieved a lower TBR (1.7 ± 1.3 % vs 3.0 ± 2.8 %, p = 0.03), and lower glucose standard deviation (37.2 ± 8.0 vs 45.5 ± 8.9, p = 0.02) than standard of care.</div></div><div><h3>Conclusions</h3><div>In this real-world study, off-label AID use during pregnancy improved TIR while decreasing TBR. While awaiting commercially available AIDs with pregnancy algorithms, standardized approaches to optimizing current systems are needed.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"228 ","pages":"Article 112454"},"PeriodicalIF":7.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}